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Background
Once a tumor lesion exceeds a few millimeters in dia-
meter, hypoxia triggers a cascade of events to allow angio-
genesis and tumor progression. As angiogenesis is
essential for tumor growth and metastasis, controlling
tumor-associated angiogenesis is a promising tactic in lim-
iting cancer progression. Melatonin has been suggested to
inhibit angiogenesis in cancers, although this effect has
not been described in breast cancer. We evaluated the
effects of melatonin treatment on angiogenesis in breast
cancer.
Materials and methods
MDA-MB-231 breast cancer cell line was cultured in
DMEM high glucose at 37°C in 5% CO2. Cells received
CoCl2 to mimic hypoxia and were then treated with mela-
tonin (1mM). Cell viability was measured by MTT assay,
and protein and gene expression were assessed by immu-
nocytochemistry and real time PCR, respectively. We per-
formed an in vivo study where cells were implanted in the
mammary gland of athymic nude mice. Mice were treated
with 1mg of melatonin or vehicle daily, administered intra-
peritoneally 1 hour before room lighting was switched off.
Tumors were measured weekly with a digital caliper and
angiogenic proteins were evaluated in mammary tumor
tissues.
Results
Melatonin in vitro treatment was able to significantly
decrease cell viability and protein expressionof the
hypoxia inducible factor 1 alpha (HIF1a), under hypoxic
conditions. Furthermore, the anti-angiogenic action of
melatonin was tested with breast cancer xenografts in
nude mice.
Conclusion
This is the first study to show that melatonin effectively
acts against angiogenesis in breast tumors, suggesting that
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